Biomarker analysis in advanced colorectal cancer patients treated with mFOLFOX6 plus bevacizumab or XELOX plus bevacizumab

Trial Profile

Biomarker analysis in advanced colorectal cancer patients treated with mFOLFOX6 plus bevacizumab or XELOX plus bevacizumab

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 20 Jan 2018 Results assessing Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 20 Jan 2018 Primary endpoint has not been met. (Correlation between plasma VEGF-A level and progression free survival), as reported in an abstract presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top